Bishal Gyawali/scri.queensu.ca
Jun 3, 2025, 09:06
Bishal Gyawali: Why Surrogate Endpoints Shouldn’t Justify Full Cancer Drug Approvals
Bishal Gyawali, Associate Professor at Queen’s University, posted on X:
“New video in my Medscape Skills Lab Video Series has just gone live. Perfect timing because this one discusses the role of surrogate endpoints in regulatory approvals- a major theme at ASCO25.
Watch or read to empower yourselves with skills so that you don’t need to outsource critical appraisal to others.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 1, 2025, 09:11
Jul 1, 2025, 08:12
Jul 1, 2025, 07:32
Jul 1, 2025, 07:24
Jul 1, 2025, 07:18
Jul 1, 2025, 06:41